Symptoms and General Pathology

All Conditions

Neoplasms

Digestive System Diseases

Heart and Blood Diseases

Wounds and Injuries

Recurrence

Liver Neoplasms

Ischemia

Reperfusion Injury

Disease Attributes

Vascular Diseases

Postoperative Complications

Hematinics

All Drugs and Chemicals

Liver Extracts

patients subjected to major hepatectomy with vascular control of blood inflow and outflow of the whole liver

patients subjected to major hepatectomy by selectively clamping the portal and hepatic vessels only of the lobe harboring the tumor

major hepatectomy with vascular control of blood inflow and outflow of the whole liver

selective hepatic vascular exclusion

major liver resection by selectively clamping the portal and hepatic vessels only of the lobe harboring the tumor

semielective hepatic vascular exclusion

Kassiani Theodoraki, PhD

Severe ischemic changes of the liver remnant after hepatectomy could expedite tumor recurrence on the residual liver. Our study aimed at assessing the effect of warm ischemic/reperfusion (I/R) injuries on surgery-to-local recurrence interval and patient overall survival, during major hepatectomies under inflow and outflow vascular control.

One hundred and eighteen patients were subjected to liver resection under total inflow and outflow vascular clamping and were assigned as study group. These individuals were retrospectively matched to 112 counterparts, who underwent liver surgery applying inflow and outflow vascular clamping only of the segment harboring the tumor, sparing the liver remnant from any I/R injury (control group). The two cohorts were compared regarding recurrence-free survival and overall survival.

Recurrence of Liver Malignancy After Ischemia/Reperfusion Injury

Does Vascular Occlusion in Liver Resections Predispose to Recurrence of Malignancy in the Liver Remnant Due to Ischemia/Reperfusion Injury?

Aretaieion University Hospital

Associate Professor of Anesthesiology

Death

Neoplasm Metastasis

Liver Cirrhosis

End Stage Liver Disease

Liver Diseases

Gastrointestinal Diseases

Liver Failure

Hepatic Insufficiency

Patients will receive DCD after therapy after the abdominal reperfusion protocol.

Abdominal Regional Perfusion

Crystal Engelage, PhD

Corrine Weernink

Ephraim S Tang, MD, MSc

Anton I Skaro, MD, PhD

The main purpose of this study is to increase the pool of organs available for donation by performing ARP to recondition donation after cardiac death (DCD) organs prior to transplantation. We will compare the outcomes of our ARP DCD liver transplants with historical data to determine the efficacy of this treatment compared to transplantation with standard DCD and donation after brain death (DBD) organs. We will also analyze biological samples from donors and recipients and compare them with outcome data in an effort to determine if any biological markers are able to predict the quality/success of the grafts.

Liver Transplantation and Limitations of DCD Transplantation:

Liver transplantation (LT) is the sole curative therapy for end stage liver disease and has emerged as the treatment of choice for hepatocellular carcinoma. Recent evidence has also demonstrated efficacy in a growing number of malignancies including intra/extra-hepatic cholangiocarcinoma, metastatic neuro-endocrine tumors, and colorectal liver metastases. Despite these advantages, LT is limited by the availability of suitable donor organs resulting in lengthened LT waitlist times. However, during this waiting period patients may deteriorate making them ineligible for LT. In the US, 16,000 patients are listed for LT, and approximately 2000 die annually while waiting for suitable organs. In 2017, over 500 Canadians were on a waiting list for LT and nearly 200 died or withdrew from the transplant list while waiting. Additionally, while LT secondary to hepatitis C is declining, nonalcoholic steatohepatitis, alcoholic liver disease and transplant oncology indications are growing, increasing the overall demand for liver transplant.

One strategy to expand the donor pool has been to optimize utilization of organs from donation after cardiac death (DCD). While outcomes of DCD kidney, pancreas and lung transplants show similar patient and graft survival to donation after brain death (DBD) transplants, DCD livers have worse patient and graft survival, higher complications, and costs, along with worse quality of life. DCD liver grafts have twice the rate of early complications including primary non-function (PNF) and early allograft dysfunction (EAD). EAD is a transient condition with the potential for graft function recovery whereas PNF is a more severe complication leading to graft failure requiring emergency re-transplantation. In the long term, the use of DCD liver allografts is associated with a 10 fold increase in biliary complications, typically resulting in graft loss or death. Moreover, there is a high cost associated with complications and readmissions following LT, which can be upwards of $50,000 per patient. Studies investigating factors contributing to these costs have revealed that DCD allografts had the greatest impact on transplant costs. Consequently, initial enthusiasm for the use of DCD livers for LT has waned such that utilization is restricted to only ideal DCD livers from younger donors with short warm and cold ischemia times. Developing methodologies to reduce the complications associated with DCD organs and improve overall outcomes would have an immense impact on the lives of transplant patients while concurrently reducing costs on the healthcare system.

Abdominal Regional Perfusion and Limitations of Normothermic Machine Perfusion:

Conventional DCD recovery utilizes a rapid recovery technique which flushes abdominal organs with cold preservation solution to slow cellular metabolism and evacuate blood/clots to preserve the integrity of the microvasculature. This is preceded by the agonal phase between withdrawal of life support and cessation of cardiac function. During this period, abdominal organs are subject to warm ischemia resulting in accumulation of toxic metabolites, depletion of intracellular energy and anti-oxidant stores, leading to exacerbation of ischemia reperfusion at the time of implantation.

Abdominal Regional Perfusion (ARP) is a technique that has been developed to recondition DCD organs prior to transplantation through the perfusion of abdominal organs in-situ with re-oxygenated blood. This process reverses the effects of ischemia and hypoxia by restoring cellular energy stores and reducing oxygen free-radicals. Additionally, this period of restored abdominal perfusion also allows for functional evaluation of organ viability prior to graft use through measurement of donor serum/bile biochemistry throughout the perfusion process, thereby maximizing the yield of high quality grafts and avoiding the use of grafts that have impaired function.

In the few studies published to date, ARP has demonstrated a decrease in biliary complications by 86%, a decrease in ischemic cholangiopathy rates from 27% to 0% and a drop in EAD from 32% to 12%. Most importantly, graft loss at 30 days was only 2% in ARP compared with 12% in conventional DCD LT. Emerging evidence suggests that with ARP, transplants performed using DCD organs can result in outcomes similar to conventional DBD donors. In addition, other investigators have successfully used ARP to further expand the DCD donor pool by including donors beyond the traditional age limit of 50 years to patients greater than 75. This approach has the potential to dramatically increase the donor pool and has even been demonstrated to improve the quality of other organs used for transplant including kidney and heart transplantation.

Although normothermic machine perfusion (NMP) systems have demonstrated non-inferiority compared to static cold storage in LT by dropping perfusate lactate, improving intraoperative mean arterial pressure, reducing vasopressor requirements and reducing blood product transfusions, the majority (80%) of these donor livers were procured from DBD donors in which static cold storage continues to be the standard of care based upon three decades of favorable outcomes. There remains a paucity of data demonstrating the benefit of NMP in the setting of expanded criteria livers from donors with advanced age, steatosis, and DCD livers where ARP has been of proven benefit. In addition, ARP may also be advantageous due to its in-situ nature with preservation of the neurohormonal axis and communication with other abdominal organs. Few clinical studies have investigated the role of measurable variables in predicting ARP-DCD transplant outcomes; however, some correlation has been found between the effects of lactate levels, transaminase levels and the level of fibrosis on donor organ function. To address these unknowns, an additional goal of this study will be to identify possible mediators for the improved outcomes with abdominal-regional perfusion, and evaluate the utility of biomarkers to predict graft function.

Abdominal Regional Perfusion in Donation After Cardiac Death for Multi-Organ Transplantation

Imaging or biochemical evidence of anastomotic stricture requiring intervention

Imaging or endoscopic evidence of bile leak requiring antibiotics or percutaneous drainage

Overall duration of stay in hospital post-transplant

Frequency of return to the operating room for any reason

Transient non-functioning of the liver transplant but with usual recovery to full functioning liver

Non-anastomotic biliary stricture without other identifiable etiology

Patient Mortality at any time post transplant

Need for retransplant secondary to graft failure of any cause, or death

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Recurrence of Liver Malignancy After Ischemia/Reperfusion Injury	NCT04257240	Ischemic Reperf... Liver Injury Cancer Recurren... Malignancy Liver Cancer	selective hepat... semielective he...	18 Years - 90 Years	Aretaieion University Hospital
Abdominal Regional Perfusion in Donation After Cardiac Death for Multi-Organ Transplantation	NCT03946852	Liver Transplan... Ischemia Reperf... Cirrhosis Liver Cancer Liver Metastase... End Stage Liver...	Abdominal Regio...	18 Years - 75 Years	London Health Sciences Centre
Recurrence of Liver Malignancy After Ischemia/Reperfusion Injury	NCT04257240	Ischemic Reperf... Liver Injury Cancer Recurren... Malignancy Liver Cancer	selective hepat... semielective he...	18 Years - 90 Years	Aretaieion University Hospital

Spots Global Cancer Trial Database for ischemia reperfusion injury